Gastric Cancer, Metabolic Syndrome
Conditions
Keywords
Metabolic syndrome, gastric cancer, omentectomy
Brief summary
Many features of the metabolic syndrome are associated with insulin resistance. And, metabolic syndrome and insulin resistance are related to visceral obesity. Therefore, the investigators hypothesized that visceral fat removal (omentectomy) can make favorable results for the insulin resistance and metabolic syndrome. As the omentectomy is optional procedure during a surgery for early gastric cancer, the investigators will divide patients randomly into two groups, total omentectomy group and omentum preserving group.
Detailed description
The investigators will compare the change of insulin resistance (HOMA-IR) and improvement of metabolic syndrome between total omentectomy and omentum preserving group.
Interventions
PROCEDUREOmentum preserving
The minimum volume of omentum (within 3cm from gastroepiploic vessel) will be removed during gastrectomy with lymph node dissection.
PROCEDURETotal omentectomy
Whole omentum will be removed during gastrectomy with lymph node dissection.
Sponsors
Chonnam National University Hospital
Dong-A University Hospital
Keimyung University Dongsan Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed adenocarcinoma in stomach * Aged≥20 years and ≤80 years * Scheduled as laparoscopic distal gastrectomy (cT1N0M0 or cT2N0M0) * Metabolic syndrome (NCEP:ATP III (National Cholesterol Education Program and Adult Treatment Panel III) -harmonizing definition criteria * ECOG 0 (Eastern Cooperative Oncology Group) * ASA score class I-III (American Society of Anesthesiologists) * patient has given their written informed consent to participate in the study
Exclusion criteria
* Simultaneously combined resection of other organ * Active other malignancy * Expected to severe intra-abdominal adhesion due to previous abdominal operation history * Uncontrolled co-morbidity * Vulnerable patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HOMA-IR change | pre-operative and post-operative 12months | HOMA-IR change after operation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| prevalence of metabolic syndrome | pre-operative and post-operative 12months | check the presence of metabolic syndrome |
| Complication | within 30days | short-term any complication related to surgery |
| HOMA-IR change according to anastomosis type | pre-operative and post-operative 12months | comparison between Billoth-II and Roux-en-Y |
Countries
South Korea
Contacts
Primary ContactSeung Wan Ryu, M.D., Ph.D.
Outcome results
None listed